On December 14, 2023, Avalo Therapeutics, Inc. closed the transaction. The company has now issued 3,627,797 Series Seed Preferred Stock and issued warrants to purchase 1,813,896 shares of common stock at a purchase price of $0.64904 per share for the gross proceeds of $2,354,585.36488. The company has paid issuance expenses of $30,000 and net proceeds is $2,324,585.36488.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.59 USD | +8.16% | +0.96% | +38.35% |
06-24 | Avalo Therapeutics Names Chief Legal Officer | MT |
06-24 | Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.35% | 13.02M | |
+18.97% | 45.34B | |
+41.98% | 40.42B | |
-10.06% | 37.92B | |
+31.15% | 31.75B | |
-7.79% | 27.71B | |
+13.32% | 26.52B | |
+43.05% | 13.96B | |
+31.28% | 12.44B | |
-7.41% | 11.26B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Avalo Therapeutics, Inc. announced that it has received $2.354585 million in funding